Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia.

Authors :: Stams WA
den Boer ML
Beverloo HB
Kazemier KM
van Wering ER
Janka-Schaub GE
Pieters R
Source :: Haematologica [Haematologica] 2005 Dec; Vol. 90 (12), pp. 1697-9.
Publication Year :: 2005
Abstract: The fusion protein TEL-AML1 in t(12;21)+ acute lymphoblastic leukemia (ALL) recruits co-repressors and histone deacetylases (HDAC), which transrepress AML1 target genes. Normal bone marrow cells were more resistant to HDAC inhibitor FK228 induced cell killing than were cells from ALL patients with or without t(12;21). FK228 induced differentiation in ALL, irrespective of the presence of t(12;21).

Subjects :: Antigens, Differentiation, B-Lymphocyte analysis
Antineoplastic Agents pharmacology
Asparaginase pharmacology
B-Lymphocytes pathology
Bone Marrow Cells drug effects
Bone Marrow Cells enzymology
Butyrates pharmacology
Cell Differentiation drug effects
Humans
Myeloid Cells drug effects
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma enzymology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma enzymology
Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
Tumor Cells, Cultured drug effects
Tumor Cells, Cultured enzymology
Antibiotics, Antineoplastic pharmacology
B-Lymphocytes drug effects
Core Binding Factor Alpha 2 Subunit analysis
Depsipeptides pharmacology
Histone Deacetylase Inhibitors
Oncogene Proteins, Fusion analysis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology

Tools